We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, monitor and analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?
What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.
The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.SIGN UP AS AN EXPERT
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.DOWNLOAD
Helping thousands of people and companies communicate and work better.
qordata Releases Open Payments Data 2016
Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
This blog follows from Part I, where we shared advice from Compliance/Transparency professionals from Shire Pharmaceuticals, Porzio Bromberg and Merz North America on how to make your datasets more robust and CMS compliant. Treat Your Data Like Someone At The CMS Or DOJ Would: Compliance teams often focus on the supply side of spend data, i.e. presentation of their individual submissions. What recedes to the backburner in such cases is the extent of scrutiny, the search for common data culprits (e.g. missing NPIs) and the questionable records that interest authorities in CMS and the DoJ. Establish a habit of treating your data to the same scrutiny regulators would. Don’t assume that just because your numbers make sense internally, they will […]
In our most recent webinar, we explored how data management processes differ in pharmaceuticals across USA. Interestingly, processes are standardized across the most compliant and transparent medical drug and device manufacturers. Based on this, we must ask: Is there one best way of going managing and leveraging spend analytics data? Yes, accounting for differences brought in by internal policy. The processes described by our panelists, April Pierce, Chrissy Bradshaw and Elizabeth Bodine from Shire Pharmaceuticals, Porzio Bromberg, and Merz North America, respectively, had quite a few steps in common: Information Sharing Must Be Proactive: This is important. Your audience, according to Elizabeth Bodine, need to know what they’re looking for. It could be performance figures, information related to KOL or […]
Do pharmaceuticals need a compass to decide their next headquarter or research center? Yes, but not quite the one you’d expect. The right compass is called qordata Compliance Insights, an analytics tool that has collected, analyzed and gleaned the most useful from the latest CMS data by geography. What do these insights tell you about the best location for your pharma investment? Zooming In Is ‘Born in America’ a prerequisite for being featured in the list of highest spenders? Not for medical drug and device companies. The top companies of foreign origin by spend were responsible for a total of $643.54 million between 2015-2016. That’s 7.87% of the total spend reported in 2016. This amount came from 108 (127 if […]